Linalool

GABA-A receptor modulation demonstrated in animal models. Anxiolytic effects confirmed in inhalation studies. Antispasmodic activity on smooth muscle documented in vitro.

Antimicrobial activity including anti-Candida effects confirmed in vitro. GABA-A receptor modulation demonstrated in animal models. Sedative effects documented in inhalation studies.

Linalool is extensively studied with multiple mechanisms confirmed in vitro and in vivo. Animal studies consistently demonstrate anxiolytic activity equivalent to diazepam at 1 mg/kg without sedation or motor impairment, attributed to selective GABA-A α2/α3 engagement. NMDA antagonism confirmed in electrophysiological studies with EC50 in the low millimolar range. Anticholinesterase activity validated in kinetic assays. A 2015 human pilot trial of coriander extract demonstrated significant anxiety reduction; larger controlled trials are needed.

Multiple rodent studies confirm linalool's anxiolytic and sedative activity in elevated plus maze, marble burying, and forced swim tests at inhalation doses achievable in aromatherapy contexts (2.5 µL/L vapor). Linalool inhalation significantly prolonged pentobarbital-induced sleep time and reduced ketamine-induced anesthesia by 30–40% in rodent anesthesia models. A 2018 randomized crossover human study found inhaled linalool reduced salivary cortisol and anxiety scores (STAI) compared to placebo in healthy volunteers undergoing experimental stress, providing first-in-human evidence for the aromatherapy application.

Linalool demonstrates anxiolytic activity in multiple clinical trials. The compound inhibits glutamatergic neurotransmission and enhances GABAergic signalling, producing dose-dependent anti-anxiety effects without motor impairment.